- Conditions
- Colorectal Cancer
- Interventions
- Enzastaurin, Placebo, Leucovorin (LV), 5-fluorouracil (5-FU), Bevacizumab (Bev)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Memphis, Tennessee • Houston, Texas • Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Biliary Tract Cancer
- Interventions
- Atezolizumab, Bevacizumab, Placebo, Cisplatin, Gemcitabine
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • Durham, North Carolina + 2 more
- Conditions
- Weight Loss, Other Effects of High Altitude
- Interventions
- Standard pro, High pro, carbo bev, placebo bev
- Other
- Lead sponsor
- United States Army Research Institute of Environmental Medicine
- Federal
- Eligibility
- 18 Years to 42 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Natick, Massachusetts
- Conditions
- Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
- Interventions
- Bevacizumab, Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim, Placebo
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 201
- States / cities
- Phoenix, Arizona • Burbank, California • Concord, California + 138 more